Intramuscular vaccine adjuvants are used to boost the immune response triggered by vaccine antigens. They help enhance both antibody levels and cytotoxic T lymphocyte response induced by the vaccine.
Intramuscular vaccine adjuvants help produce long-lasting protection against pathogens by eliciting stronger immune responses. They enable vaccines to induce immunity at lower doses of antigens and reduce the need for frequent booster doses. Common intramuscular vaccine adjuvants include mineral salts (aluminum salts), oil-in-water emulsions, liposomes, polymers, and immune-stimulating complexes.

The Intramuscular Vaccine Adjuvants Market is estimated to be valued at US$ 694.19 Mn in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

 

Market key trends:

One of the major trends fueling the growth of intramuscular vaccine adjuvants market is the increasing development of vaccines against deadly infectious diseases like COVID-19, malaria, tuberculosis, and HIV/AIDS. Moreover, adjuvants provide opportunities to design vaccines against chronic diseases including various cancers. Aluminum salts continue to dominate the intramuscular vaccine adjuvants market due to their well-established safety profile and efficacy. However, oil-in-water adjuvants are gaining more prominence lately owing to advantages like enhanced antigen incorporation and efficient immune activation. Additionally, advancement in adjuvants such as novel delivery systems utilizing nanoparticles, lipid systems, and immune stimulators is expected to open new avenues over the forecast period.

 

Porter's Analysis

Threat of new entrants: Intramuscular vaccine adjuvants market has moderate threat of new entrants due to high capital requirements for research and development.

Bargaining power of buyers: Buyers have moderate bargaining power due to availability of alternative products and need for regulatory approvals.

Bargaining power of suppliers: Suppliers have low to moderate bargaining power due to availability of substitute raw materials.

Threat of new substitutes: Threat of new substitutes is low as adjuvanated vaccines provide effective immune response against diseases.

Competitive rivalry: High due to presence of established market players.

 

SWOT Analysis

Strength: Intramuscular vaccine adjuvants improve immune response to vaccines reducing dosing. They can facilitate development of thermostable vaccines.

Weakness: High costs associated with development and regulatory requirements. Adverse reactions reported after administration of certain adjuvanted vaccines.

Opportunity: Growing demand for pandemic preparedness and thermostable vaccines especially in developing nations. Increasing research on adjuvanted vaccines for chronic diseases and cancer.

Threats: Stringent regulatory guidelines. Recalls of certain adjuvanted vaccines in past.

 

Key Takeaways

The Global Intramuscular Vaccine Adjuvants Market Growth is expected to witness high growth, exhibiting CAGR of 6.7% over the forecast period, due to increasing demand for vaccines amid pandemic outbreaks.

Regionally, North America is expected to dominate the market owing to heavy investments in research and development activities by key players. Asia Pacific is anticipated to exhibit fastest CAGR during the forecast timeline due to rising government focus on immunization programs.

Key players operating in the intramuscular vaccine adjuvants market are Novavax, Inc., Adjuvance Technologies, Inc., Invivogen, Vaxine Pty Ltd., SEPPIC, SPI Pharma, Inc., Agenus Inc., Avanti Polar Lipids, Inc., CSL Limited, and OZ Biosciences. These players are focused on new product launches and collaborations for business expansions.

Explorer more information on this topic, Please visit - 
https://www.dailyprbulletin.com/intramuscular-vaccine-adjuvants-market-share-size-and-growth-share-trends-analysis-demand-forecast/